medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Title: Stroke Volume Reserve Is an Independent Predictor of Survival and Need for
Advanced Therapies in Systolic Heart Failure Patients

Short Title: Stroke Volume Reserve in Heart Failure
Authors: Ibrahim Selevany, MD,1 Timothy Morris, MD,2 Florin Vaida, PhD,3 Eric D.
Adler, MD,1 Barry H. Greenberg, MD,1 Paul J. Kim, MD1.
1Division

of Cardiovascular Medicine, Department of Medicine, University of California,

San Diego, La Jolla, CA; 2Division of Pulmonary and Critical Care Medicine, Department
of Medicine, University of California, San Diego, La Jolla, CA; 3Division of Biostatistics
and Bioinformatics, Department of Family Medicine and Public Health, University of
California, San Diego, La Jolla, CA.
Corresponding author:
Paul J. Kim, MD
Assistant Clinical Professor
Division of Cardiovascular Medicine, Department of Medicine
Altman Clinical and Translational Research Institute
9452 Medical Center Drive, MC 7411
La Jolla, CA, USA 92037
Email: pjk017@ucsd.edu

Tel: 858-246-0638 Fax: 858-657-5028

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Background: We investigated whether stroke volume reserve (STVR) would predict 1year mortality and need for advanced therapies in heart-failure with reduced ejection
fraction (HFrEF) patients.
Methods and Results:
We retrospectively studied 104 ambulatory patients with HFrEF (59.2+10.2 years, 89%
male) referred for cardiopulmonary exercise testing (CPET). At 1 year, 39 outcomes were
observed: 16 heart-transplants (HTx), 8 left ventricular assist devices (LVAD), and 15
deaths. Stroke volume (SV) was determined by the Fick principle with established values
for C[a-v]O2 at rest and anaerobic threshold (AT). STVR was calculated by SV AT/SVrest.
Multi-predictor regression showed a correlation of STVR<1.3 (OR 7.92, p=0.002), cardiac
index by right heart catheterization<2 (OR 3.07, p=0.049), and peak VO2 below the 2016
ISHLT cut-off (OR 4.09, p=0.011). HFrEF patients with a low peak VO2 and STVR>1.3
showed similar survival compared to patients with a peak VO 2 above the ISHLT cut-off.
A scoring system was developed: STVR<1.3â€”2 points, peak VO2 below the ISHLT cutoffâ€”1 point, and cardiac index<2â€”1 point. A score of >3 demonstrated a sensitivity of
67% and specificity of 79% for 1-year events.
Conclusions: STVR is a novel parameter that may better predict 1-year outcomes than
peak VO2 in HFrEF patients.
Key Words: heart failure; prognosis; cardiopulmonary exercise; risk stratification

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Highlights
ï‚·

Peak VO2 is used to predict outcomes in HFrEF patients.

ï‚·

Peak VO2 correlates poorly with mortality due to many contributing factors.

ï‚·

STVR is a novel CPET parameter that may better predict outcomes than peak
VO2.

ï‚·

Patients with adequate peak VO2 but abnormal STVR are at high risk for 1-year
events.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Introduction
The morbidity and mortality of HFrEF patients have improved considerably over
the years since the first major heart-failure trial, the Veterans Administration Heart Failure
Trial (V-HeFT-I), was published (1-3). However, despite advancements in modern
medical therapy, there remain patients who continue to progress in their heart-failure
course and prompt evaluation for advanced heart-failure therapies (4). These patients are
considered to be in advanced or ACC/AHA Stage D heart-failure (5). Significant limitation
in exercise tolerance, typically using a threshold of peak oxygen consumption (VO2) < 1214 ml/kg/min, is a commonly cited indicator for advanced therapies by the ISHLT (6, 7).
The use of a specific peak exercise VO2 level however has several limitations
because it can be influenced by multiple other factors including muscle deconditioning,
age, gender, obesity, and anemia (8-10). Though ideally VO2 would correlate highly with
cardiac output (CO), it is fundamentally limited by the fact that it cannot account for the
change in arteriovenous difference in oxygen content (C[a-v]O2) during exercise (11). The
relationship is described by the Fick principle: peak VO 2 = peak CO x peak C[a-v]O2. As
a result, invasive assessments of hemodynamic response showed additional prognostic
value because they provide accurate measurements of peak CO (12, 13). However,
invasively derived hemodynamic measurements during exercise are difficult to perform
routinely and noninvasive measurements of CO are also technically complicated and lack
accuracy (8, 14, 15). Thus neither methods have gained widespread acceptance.
Stringer and his colleagues previously described the relationship with SV and
exercise, also recently confirmed by Gmada and coauthors (11, 16). The authors show
that SV increases during the initial and intermediate phases of exercise and peaks at AT.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Any further increase in CO is dependent on increase in heart rate. Given this consistent
relationship between VO2 and CO up to AT, we are able to accurately estimate the
increase in SV at AT non-invasively.
In this study, we evaluated the prognostic significance of SV at AT divided by SV
at rest, defined as STVR, in HFrEF patients compared to the usual measures of CPET,
i.e., peak VO2, VO2 at AT (AT VO2), and minute ventilation divided by carbon dioxide
output (VE/VCO2). To date, no study utilizing STVR for risk stratification in HFrEF patients
have been performed. We hypothesized that STVR would better predict mortality, LVAD
implantation, or HTx in HFrEF patients.

Methods
Study Population and Design
We retrospectively analyzed 104 HFrEF patients who underwent CPET at the
University of California, San Diego (UC San Diego), physiology laboratory for advanced
therapies evaluation consecutively between January 2017 and September 2018. Patients
with left ventricular ejection fraction (LVEF) < 35% by echocardiography and New York
Heart Association (NYHA) class II to IV were included. Patients less than 18 years old,
with

congenital

heart

disease,

planned

coronary

revascularization,

previous

transplantation, requiring intravenous inotropic therapy or failing to reach AT were
excluded.
Exercise Protocol

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Incremental symptom-limited CPET was performed using a V-max metabolic cart
(CareFusion, San Diego, CA). A technician selected an appropriate step-wise treadmill
exercise protocol based on the patientâ€™s weight and expected work expenditure (50, 100,
or 150 Watts). All patients performed exercise testing on a treadmill. The treadmill
protocols had been clinically validated within each weight interval to produce a uniform
increase in mechanical work and metabolic energy expenditure per incremental step.
Each patient performed a maximum voluntary ventilation maneuver prior to exercise. A
calibrated ptcCO2 sensor was placed in the subclavicular skin or ear lobe position,
depending on patient preference. Exhaled gases, electrocardiography and pulse oximetry
were measured continuously. After a 2-3-minute period of standing at rest, each patient
exercised with one-minute incremental increases in workload until the point of exhaustion.
Minute ventilation (VE), VO2, carbon dioxide output (VCO2), and other cardiopulmonary
variables were acquired on a breath-by-breath basis and averaged over 30-second
intervals. Within each increment, the ptcCO2 reading at 30 seconds was accepted as an
estimate of the paCO2 for the entire increment. The ventilatory AT was detected by the Vslope method (17).
SV at rest and at AT
SV during rest and at AT were reflected noninvasively by the equation: SV = (VO 2
/ heart rate) / C[a-v]O2. The C[a-v]O2 was estimated to be 6.1 ml O2 / 100 ml blood at rest
and 11.3 ml O2 / 100 ml blood at AT. The estimates of C[a-v]O2 at rest and at AT reflect
the values consistently measured by arterial and pulmonary artery blood sampling in
healthy subjects and in patients at various stages of heart failure (18-21). They also
approximate the C[a-v]O2 we have measured at rest and at AT in patients with pulmonary

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

hypertension who underwent exercise testing in our centerâ€™s catheterization laboratory
with pulmonary artery and arterial catheters in place (unpublished communication).
Previous invasive experiments on healthy subjects demonstrated an increase in the
stroke volume by approximately 40% at AT when compared to rest (22-25).
Outcomes and Data Acquisition
The primary outcome was a composite of death, HTx or LVAD implantation 1 year
after performance of CPET. Outcomes determined by chart review and patient follow up
via phone calls for patients that were not seen in the hospital system within the past 3
months. All of the authors have full access to the data in the study and take full
responsibility for its integrity and the analysis. All aspects of this study were approved by
the UC San Diego Human Research Protections Program.
Right heart catheterization data was obtained within 30 days of CPET for 82 of the
104 patients. Pulmonary vascular resistance (PVR) was calculated as: PVR (Wood units)
= [mean pulmonary artery pressure (PA) - pulmonary capillary wedge pressure (PCWP)
/ CO. Transpulmonary gradient (TPG) was calculated as: TPG (mmHg) = mean PA PCWP. The RV stroke work index (RVSWI) was calculated as (mean PA - mean RA) x
SV index x 0.0136 (g-m2/beat). All other clinical data was obtained at the time of CPET.
Statistical Analysis
The predictors of 1-year composite outcome were identified using single- and
multi-predictor logistic regression. Multi-predictor logistic regression used backwards
model selection, starting with the covariates significant at p<0.05 in single-predictor
models, and with a p<0.05 threshold for inclusion. As an additional step, the predictors

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

from the final multi-predictor model were dichotomized using defined cut-offs. The cut-off
values for STVR and cardiac index were chosen to minimize the Euclidian distance from
the receiver-operating-characteristic (ROC) curve to the upper-left corner of the ROC
graph, in effect maximizing a combination of sensitivity and specificity (26, 27). For the
other parameters in our model, including peak VO2, Heart Failure Survival Score (HFSS)
score, and Kato model score, previous studies and the 2016 ISHLT guidelines for hearttransplant listing (7, 28) were used for selection of the cut-off values. Based on the final
multi-predictor logistic regression model, which included the dichotomized STVR, peak
VO2, and cardiac index, we created a â€œSTVR risk scoreâ€, which uses simple integer
weights for each of the three covariates, based on their model coefficient (i.e., log odds
ratio), with the lowest coefficient receiving 1 point, as a reference value. The reason for
using the logistic regression model coefficients as a basis for the score is that in the
predictive model the risk score is linearly associated with the log-odds of the event. This
method is similar but not identical to that of Kato et al (28).
To validate the independence of each predictive covariate, we investigated the
predictive ability of three clinically validated risk stratification scores, namely the HFSS
score, Seattle Heart Failure Model (SHFM) score, and the Kato model score (28-30) and
subsequently included the HFSS score and the Kato model score into our final multipredictor logistic regression model. HFSS is calculated using an algorithm which accounts
for the presence of multiple prognostic risk factors and baseline clinical characteristics,
specifically the presence of coronary artery disease, resting heart rate, mean arterial
blood pressure, left ventricular ejection fraction, presence or absence of interventricular
conduction defect, peak VO2, and serum sodium (30-32). The Kato model score is a

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

recently described risk stratification tool that non-invasively assessed markers of left
sided and right sided congestion to guide risk assessment (28).
The time-to event distributions were generated separately for the two groups
based on STVR below and above the threshold, and for the four groups based on the
cross-classification of STVR below/above threshold and peak VO2 below/above
threshold, using the Kaplan-Meier estimator. The relative risk in the different groups was
assessed via the hazard ratio from the Cox proportional hazards model, and group
comparison was based on the log-rank test.
In supplemental analyses, we compared the demographic and clinical
characteristics of the two cohorts with STVR above and below the cut off. Comparison of
variables used independent Studentâ€™s t-tests for continuous variables, and Fisherâ€™s exact
test for binary variables.
In all analyses p < 0.05 was considered significant; two-sided hypothesis tests and
confidence intervals were used throughout. Statistical analyses were performed using
Prism 8 for Windows (GraphPad Software, Inc, San Diego, CA) and Excelâ€™s XLMiner
Analysis ToolPak (Microsoft Excel; Microsoft Corp, Bellevue, WA).

Results
Clinical Characteristics and 1-year Outcomes
The clinical characteristics of the study population are summarized in Table 1. The
mean age of the patients was 59 years, 89% were male, and 51% had an ischemic

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

etiology. The majority of the patients were on appropriate medical therapy with 88% on
ð›ƒ-blocker therapy, 25% also requiring digoxin or ivabradine, 95% on either ACEI/ARB,
ARNI or isosorbide dinitrate/hydralazine therapy, and 84% received either a CRT or an
ICD. All patients had symptomatic heart failure, with a mean NYHA class of 2.8 + 0.6.
Mean peak VO2 at the time of HTx evaluation was 15.5 ml/kg/min and mean LVEF was
22.3%. The mean HFSS of our cohort was 8.0. We were able to obtain hemodynamic
data on 82 of the 104 patients. The mean RA pressure was 8.9 mmHg, PCWP was 18.2
mmHg, PVR 2.8 Wood units and cardiac index of 2.2 liters/min/m2.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 1. Clinical Characteristics of Patients at Time of CPET
Clinical Characteristics (n=104)
Age, years, mean (SD)
Male, n (%)
Body mass index, kg/m2, mean (SD)
NYHA class, mean (SD)
Ischemic etiology, n (%)
Diabetes mellitus, n (%)
Chronic kidney disease, Stage III or greater, n (%)
Pulmonary disease, n (%)
HFSS, mean (SD)

59.2 (10.8)
93 (89.4)
28.9 (5.5)
2.8 (0.6)
51 (49.0)
36 (34.6)
48 (46.2)
13 (12.5)
8.0 (0.9)
Medications

Diuretics, n (%)
Digoxin, n (%)
ð›ƒ-blockers, n (%)
Ivabradine, n (%)
Aldosterone antagonist, n (%)
ACEI/ARB or isosorbide dinitrate/hydralazine, n (%)
ARNI, n (%)
Pacing Devices
CRT, n (%)
ICD, n (%)
Hemodynamic Data
Mean RA, mean (SD), mmHg
Mean PA, mean (SD), mmHg
PCWP, mean (SD), mmHg
TPG, mean (SD), mmHg
RVSWI, mean (SD), g-m2/beat
PVR, mean (SD), Wood units
Cardiac index, mean (SD), liters/min/m2
Mixed venous oxygen saturation, mean (SD), %
CPET Parameters
Peak VO2, mean (SD), ml/kg/min
VE/VCO2 Slope, mean (SD)
Echocardiographic data
LVEF, mean (SD), %
LV end-diastolic dimension in mm, mean (SD)
Mitral regurgitation, 2+ or greater, n (%)
Laboratory Data
Creatinine, mean (SD), mg/dl
BUN, mean (SD), mg/dl
Sodium, mean (SD), mEq/liter
Hemoglobin, mean (SD), g/dl
Total bilirubin, mean (SD), mg/dl
AST, mean (SD), U/liter
ALT, mean (SD), U/liter

92 (88.5)
17 (16.3)
92 (88.5)
8 (7.7)
74 (71.2)
40 (38.5)
58 (55.8)
62 (59.6)
87 (83.7)
8.9 (5.4)
29.3 (13.8)
18.2 (8.8)
11.1 (4.8)
7.6 (3.4)
2.8 (1.9)
2.2 (0.6)
63.6 (10.2)
15.5 (5.3)
33.7 (6.8)
22.6 (7.2)
63.3 (10.0)
30 (28.8)
1.4 (1.3)
26.9 (15.9)
137.9 (3.7)
13.9 (1.8)
1.0 (0.9)
28.1 (16.7)
30.7 (30.9)

Means (SD) reported for continuous variables, and n (%) for binary variables. ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker; ARNI, angiotensin receptor-neprolysin inhibitor; CRT, cardiac resynchronization therapy; ICD,
implantable cardioverter-defibrillator.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Among 104 patients, 16 patients (15.4%) required HTx, 8 required LVAD (7.7%)
and 15 (14.4%) patients died within 1 year after HTx evaluation. Thus, a total of 39
patients (37.5%) reached the primary composite end-point.
Univariate Analysis of Factors Associated with 1-Year Events
The results of the association of factors with 1-year events are shown in Table 2.
As continuous variables, higher NYHA functional class, lower STVR, higher VE/VCO 2
slope, lower AT VO2, lower peak oxygen pulse, lower HFSS score and decreased
hemoglobin levels were found to be significantly associated with events after HTx
evaluation. In addition, several hemodynamic parameters obtained from right heart
catheterization, including higher mean RA pressure, higher mean PA pressure, higher
PCWP, lower mixed venous oxygen saturation and decreased cardiac index, were
associated with one-year events. Lower RVSWI was not found to associated with 1-year
events in this patient population. As categorical variables, a score>4 by the Kato model
score was significantly correlated with 1-year events while the SHFM score predicting <
80% 1-year survival was not.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 2. Factors Associated With 1-Year Composite Events in Single-Predictor Logistic
Regression
Variables
Age (years)
NYHA class
STVR
Peak VO2 (ml/kg/min)
AT VO2 (ml/kg/min)
VE/VCO2 slope
Peak oxygen pulse
(ml/beat)
Mean RA (mmHg)
Mean PA (mmHg)
PCWP (mmHg)
RVSWI (g-m2/beat)
PVR (Wood units)
TPG (mmHg)
Mixed venous oxygen
saturation (%)
Cardiac index
(liters/min/m2)
Hemoglobin (g/dl)
Sodium (mEq/liter)
Creatinine (mg/dl)
HFSS
SHFM*
Kato (28) model score*

OR (95% CI)
1.022 (0.976, 1.071)
4.552 (1.713, 12.098)
0.0173 (0.002, 0.143)
0.736 (0.627, 0.863)
0.801 (0.672, 0.954)
1.116 (1.030, 1.188)
0.781 (0.683, 0.920)

P value
0.35
0.002
<0.001
<0.001
0.013
0.006
0.003

1.115 (1.023, 1.217)
1.045 (1.003, 1.088)
1.066 (1.010, 1.125)
0.911 (0.796, 1.042)
0.977 (0.893, 1.070)
1.041 (0.938, 1.155)
0.890 (0.833, 0.948)

0.013
0.034
0.020
0.17
0.62
0.45
<0.001

0.207 (0.072, 0.594)

0.003

0.666 (0.489, 0.906)
0.900 (0.794, 1.018)
0.999 (0.707, 1.411)
0.298 (0.155, 0.587)
1.68 (0.572, 4.921)
8.438 (1.686, 42.223)

0.010
0.095
0.95
0.005
0.35
0.009

CI, confidence interval; OR, odds ratio. See Table 1 and text for other abbreviations.
* Indicates a categorical variable.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Multi-predictor Logistic Regression of Factors Associated with 1-Year Events

Subsequently, STVR, peak VO2, AT VO2, VE/VCO2 slope, peak oxygen pulse,
mean RA pressure, mean PA pressure, PCWP, cardiac index, mixed venous oxygen
saturation, hemoglobin level, NYHA class, and HFSS were included in the multi-predictor
model. Stepwise backward logistic regression was used to arrive at the final predictive
model (table 3)â€”notably STVR<1.3, peak VO2<12 to 14 ml/kg/min or < 50% predicted
as per the 2016 ISHLT heart-transplant listing guidelines (7), and cardiac index<2.0 were
independently associated with clinical outcomes.

The HFSS score and Kato model score was subsequently added to a separate
multi-predictor model as previously describedâ€”the results of these three separate multipredictor models are shown in table 3. The OR was highest using STVR<1.3 and notably
higher than using peak VO2 criteria as per the ISHLT cut-off. Furthermore, STVR retained
its predictive ability when combined with the HFSS and the Kato model score in separate
models.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 3. Multi-predictor Logistic Regression of Factors Associated with 1-Year Events.
Covariates were dichotomized using published or data-based cut-offs.
Model 1

Model 2

Model 3

Predictors

OR (95% CI)

P value

OR (95% CI)

P Value

OR (95% CI)

P value

STVR<1.3

7.924 (2.17, 29.11)

0.002

8.292 (2.10, 32.79)

0.003

9.299 (2.25, 38.42)

0.002

Cardiac Index<2.0

3.065 (1.01,9.35)

0.049

3.400 (1.06, 10.92)

0.040

2.829 (0.89,8.95)

0.077

Peak VO2 below 2016
ISHLT cut-off (7)

4.092 (1.38,12.12)

0.011

3.412 (1.11, 10.51)

0.033

3.440 (1.10,10.78)

0.034

HFSS<8.1

NA

--

3.593 (1.04, 12.39)

0.043

NA

--

Kato model Score

NA

--

NA

--

9.165 (1.29, 65.38)

0.027

CI, confidence interval; OR, odds ratio
Model 1 contains the covariates from Table 2 that were found to be significant with backward logistic regression, namely STVR,
cardiac index, and peak VO2. Model 2 contains the covariates from table 1 in addition to the HFSS score as described in the
methods section. Model 3 contains the covariates from model 1 in addition to the Kato (28) model score, Kato model score>4
considered positive with 2 points for PCWP>20, 2 points for RVWSI<5, 1 point for MELD-A>14, and 1 point for peak VO2<14. See
text for other abbreviations.

Comparison of HFrEF Patients Dichotomized by STVR

Using the cut-off of STVR<1.3, we categorized the HFrEF patients into two groups,
patients with normal STVR and patients with abnormal STVR as shown in Supplementary
Table S1. Interestingly, the two groups were remarkably similar in their clinical
characteristics with significant differences seen only in HFSS score, diuretic use, and
hemoglobin level. Abnormal CPET parameters differentiated the two groups further with
significantly decreased exercise time, AT SV, AT VO2, peak VO2, and VE/VCO2 slope in
the abnormal STVR group. When comparing the AT SV to rest SV, the normal STVR
patients showed the expected greater than 30% increase in SV at AT while the abnormal
STVR patients showed a trend towards slight decrease in SV at AT compared to SV at
rest. The comparison between these two patient groups exemplify the importance and
need for using CPET to identify patients who are at high risk for 1-year events.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Kaplan-Meier Survival Curves and ROC Analysis

The event-free rate from the time of HTx evaluation of patients with STVR > 1.3
and those < 1.3 is shown in Figure 1. The area under the curves of ROC analysis for
STVR was 0.865 and higher than any other single factor as shown in Figure 2A.

We subsequently created our own STVR risk score, as described in the statistical
methods section. In this model, STVR<1.3 is weighted 2 points, and peak VO2 below the
ISHLT cut-off and cardiac index<2.0 were both weighted 1 point. The ROC analysis using
this model showed that a cut-off of > 3 points yielded a sensitivity of 66.7%, a specificity
of 83.0% and the highest predictive accuracy of 76.3% for association with 1-year events
after CPET. In comparison with HFSS, SHFM and Kato risk model scores, we found the

Event Free Survival (%)

STVR risk score had the highest area under the curve of 0.91 as shown in Figure 2B.

100
90
80
70
60
50
40
30
20
10
0

86%

Normal STVR

46%

Abnormal STVR

Log-Rank p<0.001
0

50

100

150

200

250

300

350

Duration of Event Freedom (Days)
Figure 1. Kaplan-Meier Curves of HFrEF patients after CPET classified as abnormal STVR (STVR<1.3)
and normal STVR (STVR>1.3). The end-point was set as death, LVAD implantation, or HTx. Patients with
normal STVR showed significantly higher event free survival compared to abnormal STVR patients.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

A

1.00

Sensitivty

0.75
0.50
0.25
0.00
0.00

0.25

0.50

0.75

1.00

1-Specificity
AT VO2 Area: 0.676 (95% CI 0.571-0.781, p<0.001)
Peak VO2 Area: 0.774 (95% CI 0.684 - 0.865, p<0.001)
STVR Area: 0.865 (95% CI 0.795- 0.936, p<0.001)
PCWP Area: 0.678 (95% CI 0.573 - 0.783, p<0.001)

B 1.00

Sensitivty

0.75
0.50
0.25
0.00
0.00

0.25

0.50

0.75

1.00

1-Specificity

STVR Model AUC: 0.907 (95% CI 0.836-0.966), p<0.001
HFSS AUC: 0.785 (95% CI 0.697-0.874), p<0.001
Kato Model AUC: 0.852 (95% CI 0.764-0.940), p<0.001
SHFM AUC: 0.680 (95% CI 0.582-0.778), p<0.001

Figure 2. A) ROC curves for AT VO2, peak VO2, STVR, and PCWP. B) ROC curves for our STVR risk
score, HFSS, Kato model, and SHFM scores. The AUC was highest for STVR compared to other singlepredictors and highest for the STVR risk score compared to other risk score models. AUC (c-statistic) and
the respective 95% CI are listed.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Kaplan-Meier Survival Curves Using Cross-classification of STVR and Peak VO2

Figure 3 shows STVR provides additional useful prognostic information and can
be used to further risk stratify HFrEF patients beyond peak VO2. Figure 4 demonstrates
a useful schematic for cross-classification of HFrEF patients by STVR and peak VO 2.
Patients with peak VO2 above the 2016 ISHLT cut-off and abnormal STVR demonstrated
similar prognosis to HFrEF patients with peak VO2 below the ISHLT cut-off that were not
significantly different (Supplemental Figure S1). HFrEF patients with a peak VO2 below
the ISHLT cut-off but normal STVR showed similar prognosis to HFrEF patients with peak
VO2 greater than the ISHLT cut-off that were not significantly different (Supplemental
Figure S2). Cox proportional hazards analysis including STVR and peak VO2 as risk
factors for the composite event showed that abnormal STVR (HR 5.47, 95% CI 1.91,
15.62, p<0.002) and peak VO2 below the ISHLT cut-off (HR 2.71, 95% CI 1.35, 5.43,
p=0.005) were both independently predictive of clinical events. Supplemental figure S3
shows cross-classification into four cohorts using STVR and peak VO 2. The top two
cohorts with the best survival were defined by normal STVR while the bottom two cohorts
with the worst survival were defined by abnormal STVR.

Event Free Survival (%)

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Peak VO2 below ISHLT
cut-off and normal
STVR (n=9)

100
90
80
70
60
50
40
30
20
10
0

78%

61%

42%

Peak VO2 above ISHLT
cut-off (n=67)
Peak VO2 above ISHLT
cut-off and abnormal
STVR (n=33)
Peak VO2 below ISHLT
cut-off (n=37)

0

50

100

150

200

250

300

350

Duration of Event Freedom (Days)
Cox proportional HR
STVR<1.3: 5.47 (1.91,15.62), p<0.002
Peak VO2<ISHLT: 2.71 (1.35,5.43), p=0.005

Figure 3. Kaplan-Meier survival curves of HFrEF patients by peak VO2 with two subgroups
additionally cross-classified by STVR. The solid gray and black lines represent patients stratified
by peak VO2 using the 2016 ISHLT criteria. The dashed black and gray lines represent patients
further cross-classified by STVR. Despite low peak VO2, patients with normal STVR performed
similarly compared to patients with peak VO2 above the ISHLT cut-off. Additionally, despite
â€œadequateâ€ peak VO2 above the ISHLT cut-off, patients with abnormal STVR demonstrated a low
event free survival that was similar to patients with a low peak VO2. STVR<1.3 and peak VO2
below the ISHLT cut-off were analyzed in a multi-predictor Cox proportional hazards model to
derive the hazard ratios listed in the figure and their corresponding 95% confidence intervalsâ€”
the reference group was STVR>1.3 and peak VO2 above the ISHLT cut-off.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 4. Schematic using cross-classification of HFrEF patients by STVR below/above 1.3 threshold and
peak VO2 below/above 2016 ISHLT cut-off.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Discussion
Major Findings
In the present study, we have demonstrated that: (i) STVR, a novel CPET
parameter, is a better predictor of 1-year events, including death, HTx and LVAD
implantation, in HFrEF patients than traditional CPET parameters, i.e., peak VO2, AT VO2,
and VE/VCO2 slope; (ii) ambulatory HFrEF patients with an abnormal STVR have a
significant 1-year event rate of 54.1%; (iii) HFrEF patients with an abnormal STVR had a
poor 1-year prognosis regardless of their peak VO2; (iv) the novel risk-stratification model,
consisting of a simple scoring system of STVR<1.3 = 2 points, peak VO2 < ISHLT cut-off
= 1 point, and cardiac index<2 = 1 point, could sufficiently discriminate patients with a
high risk for 1-year events in this cohort.
STVR and CO
Peak VO2 derived from CPET has modest correlation with peak CO because it is
influenced by multiple additional factors, including age, gender, muscle deconditioning,
obesity, anemia, lung function, use of ð›ƒ-blockers, and also congenital heart disease (9,
10, 33). As a result, invasive hemodynamic parameters, usually CO, cardiac power output
or stroke work index, provided additional prognostic information beyond measurement of
peak VO2 (12, 13). In particular, in HFrEF patients with a peak VO2 below 14 ml/kg/min,
those patients who demonstrated a normal CO response demonstrated a similar survival
to patients with a peak VO2 greater than 14 ml/kg/min. Thus estimates of hemodynamic
parameters also discriminated between high and low risk patients among HFrEF patients
with low exercise tolerance (34).

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

SV correlates highly with VO2 during the initial and intermediate phases of exercise
up to the AT (11, 14, 16). However, after AT, SV will plateau and this relationship no
longer holds due to the relatively low r-squared between VO2 and arteriovenous oxygen
difference beyond 60% of maximal aerobic power (11, 16). Any further increase in CO
after AT is dictated by heart rate since the SV is essentially fixed. This understanding of
the relationship between SV and VO2 during exercise likely explains the limitation of using
peak oxygen pulse or peak VO2 pulse as a surrogate for SV despite accounting for heart
rate (11, 35, 36). Thus, we utilized the strong and predictable linear relationship with SV
and VO2 during the initial and intermediate exercise periods to calculate the STVR,
defined as SV at AT / SV at rest. Using previously published data from healthy subjects,
patients with HFrEF and patients with severe COPD, we subsequently defined a cut-off
by the area under the ROC curve to be STVR<1.3 to identify HFrEF patients with
abnormal STVR (16, 18-20, 22).
Therefore, we were able to use STVR as a noninvasive measure of CO response
at AT. By measuring the response in SV, this eliminates other contributing factors of peak
VO2. The reserve component of STVR is particularly novel. Other CPET parameters use
absolute thresholds despite patient differences or attempt to account for some of these
confounding variables using percent predicted thresholds. However, for all patients, we
still would reasonably expect them to mount an appropriate cardiac reserve to increased
metabolic demands. Thus, STVR identifies those high risk HFrEF patients who are unable
to demonstrate an appropriate increase in SV at AT. An additional value of STVR, that
should not be overlooked, is that it can be measured in patients who do not achieve
adequate exercise effort, often defined as a respiratory exchange ratio < 1.05, as long as

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

AT is reached. Of note, we observed an increased risk in death in patients who failed to
reach AT, a correlation also previously noted by Agostoni and colleagues (37). In the
current study, three out of the five HFrEF patients who failed to reach AT died within one
year. These patients were not included in this study.
Risk-stratification in HFrEF Patients
Currently, there are no universal criteria for identifying HFrEF patients who should
be evaluated for advanced heart-failure therapies (4). As a result, risk scores such as the
SHFM and HFSS are often used to identify HFrEF patients at high risk for 1-year events.
However, these scores show only fair prognostic accuracy (38) and in fact, only the HFSS
score showed predictive value in this study. The Kato model score (28), which focuses
on measures of surrogate markers of left and right sided dysfunction, showed predictive
value in our study and performed similarly to STVR alone, corroborating the utility of
STVR in risk stratification. Furthermore, our novel STVR risk score demonstrates superior
predictive accuracy compared to Kato model score. Thus, in a patient population where
accurate predictive factors have been historically difficult to identify, we show the
significant incremental value of utilizing STVR. In particular, STVR is most valuable in
identifying HFrEF patients at high risk for 1-year events who were initially considered low
risk by peak VO2 alone with â€œadequateâ€ exercise tolerance. While these patients
(adequate peak VO2 with abnormal STVR) were thought to have favorable prognosis
associated with adequate peak VO2, poor cardiac reserve indicated by abnormal STVR
identifies their true high risk status inherently related to their end-stage cardiomyopathy.
Conversely, HFrEF patients that were initially considered to be high risk by peak VO2 who
demonstrate a normal cardiac reserve by STVR show a similar survival compared to

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

patients with a peak VO2 greater than the ISHLT cut-off. In other words, HFrEF patients
with low peak VO2 but normal STVR have other reasons that contribute to the low peak
VO2, such as deconditioning and anemia, which may improve with interventions such as
cardiac rehabilitation and improved nutritional status. Thus, cross-classification of HFrEF
patients using both STVR and peak VO2 may identify patients with â€œreversibleâ€ factors
(low peak VO2 with normal STVR) whose overall prognosis can improve while identifying
patients with poor cardiac reserve who remain at high risk for 1-year events despite their
seemingly adequate exercise tolerance (adequate peak VO2 with abnormal STVR).
Methodologic Considerations and Future Directions
Our study contains several limitations. First, this is a single center retrospective
cohort study and thus our observations need to be validated in other centers with larger
patient samples to confirm our results. Our patient population was predominantly older
males with coronary artery disease. That being said, our patient population is not
dissimilar to other studies evaluating HFrEF patients (2, 28, 39). Second, we did not
confirm our estimates of SV with noninvasive nor invasive determinations of CO.
Confirmation with direct measures of CO will help confirm whether inappropriate increase
in CO is the underlying reason for why STVR is able to identify patients at high risk for 1year events. Third, the VE/VCO2 slope was not measured through the entire exercise
period and instead, determined up to the AT. This was done by convention because of
the known steepening of VE beyond the anaerobic threshold for ventilatory compensation
for metabolic acidosis (14). However, other studies have shown additional clinical
information with use of all exercise data and therefore, there is a possibility that VE/VCO2
slope calculated from data throughout the exercise period would show further predictive

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

value (40, 41). Finally, this study was conducted using treadmill exercise only (preferred
modality in the United States (14)) and thus it is unknown whether the same conclusions
can be made in CPETs using a stationary cycle ergometer.
Future studies using STVR should be considered in other patient populations with
heart-failure, specifically heart-failure with preserved ejection fraction and congenital
heart disease patients. Additionally, it would be interesting to evaluate whether STVR can
accurately identify HFrEF patients who can significantly increase their peak VO2 after
cardiac rehabilitation. Finally, this study was conducted during the transition to the heart
allocation change by UNOS that took place in November 2018. Future studies will have
to take this into consideration as we would expect it change the time to hearttransplantation in ambulatory HFrEF patients.
Conclusion
STVR is a novel CPET parameter that better predicts 1-year prognosis than peak
VO2, VE/VCO2 slope and AT VO2 in HFrEF patients. Our STVR risk score using cut-off
values consisting of STVR<1.3, peak VO2 below the ISHLT cut-off, and cardiac index<2
shows improved prognostic accuracy compared to currently used risk scores such as
SHFM, HFSS and the Kato model score. Therefore, STVR should be considered when
evaluating HFrEF patients for advanced therapies.

Disclosures
None.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Supplementary Table and Figures
Table S1. Clinical Characteristics between Normal and Abnormal SVTR Groups
Normal STVR (n=43)

Abnormal STVR (n=61)

P-Value

Age, years, mean (SD)

57.1 (10.8)

60.7 (10.1)

0.091

Male, n (%)

38 (88.4)

55 (90.2)

0.79

Body mass index in kg/m , mean (SD)

28.8 (6.4)

29.0 (4.9)

0.88

NYHA class, mean (SD)

2.8 (0.6)

2.8 (0.5)

0.97

Ischemic etiology, n (%)

20 (46.5)

31 (50.8)

0.47

Diabetes mellitus, n (%)

15 (34.9)

21 (34.4)

0.85

Chronic kidney disease, Stage III or
greater, n (%)
Pulmonary disease, n (%)

19 (44.2)

29 (47.5)

0.62

5 (11.6)

8 (13.1)

0.79

HFSS, mean (SD)

8.3 (1.1)

7.7 (0.7)

0.002

Kato Model Score, mean (SD)

1.6 (1.5)

2.2 (1.4)

0.081

Diuretics, n (%)

34 (79.1)

58 (95.1)

0.023

Digoxin, n (%)

5 (11.6)

12 (19.7)

0.31

ð›ƒ-blockers, n (%)

39 (90.7)

53 (86.9)

0.72

Ivabradine, n (%)

3 (7.0)

5 (8.2)

0.82

Aldosterone antagonist, n (%)

30 (75)

41 (69)

0.54

ACEI/ARB or nitrates, n (%)

14 (35)

21 (36)

0.90

ARNI, n (%)

22 (55)

33 (56)

0.99

2

Medications

Pacing Devices
CRT, n (%)

24 (55.8)

38 (62.3)

0.51

ICD, n (%)

34 (79.1)

53 (86.9)

0.29

Mean RA, mean (SD), mmHg

7.7 (4.4)

9.6 (5.9)

0.15

Mean PA, mean (SD), mmHg

27.4 (10.6)

30.2 (12.3)

0.32

PCWP, mean (SD), mmHg

17.0 (7.8)

18.8 (9.2)

0.40

TPG, mean (SD), mmHg

10.3 (4.7)

11.4 (4.9)

0.36

RVSWI, mean (SD), g-m2/beat

7.7 (3.7)

7.5 (3.3)

0.90

PVR, mean (SD), Wood units

2.5 (1.8)

3.0 (1.9)

0.25

Cardiac index, mean (SD),
liters/min/m2
Mixed venous oxygen saturation,
mean (SD), %

2.3 (0.8)

2.1 (0.5)

0.16

67.5 (9.6)

63.6 (10.0)

0.11

Hemodynamic Data

CPET Parameters
Exercise time, mean (SD), s

572.3 (184.2)

443.7 (172.6)

<0.001

Rest SV, mean (SD), ml/beat

67.04 (20.0)

75.4 (26.8)

0.053

AT SV, mean (SD), ml/beat

105.5 (36.9)

73.5 (27.1)

<0.001

AT VO2, mean (SD), ml/kg/min

13.2 (4.5)

8.8 (2.3)

<0.001

Peak Oxygen Pulse, mean (SD),
ml/beat
Peak VO2, mean (SD), ml/kg/min

12.3 (5.1)

10.5 (3.5)

0.12

18.9 (5.9)

13.7 (4.1)

<0.001

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

VE/VCO2 slope, mean (SD)

33.4 (5.4)

39.9 (6.8)

<0.001

Peak HR, mean (SD), bpm

125.3 (25.2)

117.0 (22.4)

0.071

Peak SBP, mean (SD), mmHg

129.1 (20.9)

121.5 (19.3)

0.062

Peak RER, mean (SD)

1.1 (0.1)

1.1 (0.1)

0.94

Echocardiographic data
LVEF, mean (SD), %

24.1 (8.0)

21.3 (7.0)

0.062

LV end-diastolic dimension, mean
(SD), mm
Mitral regurgitation, 2+ or greater, n
(%)

61.5 (9.4)

64.4 (10.2)

0.15

10 (23.3)

20 (32.8)

0.29

Laboratory Data
Creatinine, mean (SD), mg/dl

1.5 ( 0.7)

1.4 (0.8)

0.77

BUN, mean (SD), mg/dl

25.9 (19.6)

27.5 (12.7)

0.64

Sodium, mean (SD), mEq/liter

137.4 (3.3)

138.2 (3.9)

0.31

Hemoglobin, mean (SD), g/dl

14.4 (1.6)

13.6 (1.8)

0.019

Total bilirubin, mean (SD), mg/dl

0.9 (1.1)

1.1 (0.9)

0.53

AST, mean (SD), units/liter

27.8 (15.8)

28.3 (17.3)

0.90

ALT, mean (SD), units/liter

33.3 (31.8)

26.7 (17.1)

0.19

Means (SD) reported for continuous variables, and n (%) for binary variables. See Table 1 and text for abbreviations.

Event Free Survival (%)

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

100
90
80
70
60
50
40
30
20
10
0

61%
42%

Peak VO2 above ISHLT
cut-off and abnormal
STVR (n=33)
Peak VO2 below ISHLT
cut-off (n=37)

Log-Rank p=0.20

0

50

100

150

200

250

300

350

Duration of Event Freedom (Days)

Figure S1. Kaplan-Meier survival curves of HFrEF patients with peak VO2 below the ISHLT cut-off (solid
line) in comparison to patients with peak VO2 above the ISHLT cut-off and with abnormal STVR (gray line).
No significant differences were present in the event free survival between the two groups.

Event Free Survival (%)

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

100
90
80
70
60
50
40
30
20
10
0

78%
74%

Peak VO2 below ISHLT cut-off
and normal STVR (n=9)
Peak VO2 above
ISHLT cut-off (n=67)

Log-Rank p=0.72

0

50

100

150

200

250

300

350

Duration of Event Freedom (Days)
Figure S2. Kaplan-Meier survival curves of HFrEF patients with peak VO2 greater than the ISHLT cut-off
(solid black line) in comparison to patients with peak VO2 below the ISHLT cut-off and with normal STVR
(dotted black line). No significant differences were present in the event free survival between the two
groups.

Event Free Survival (%)

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

100
90
80
70
60
50
40
30
20
10
0

88%
78%
61%

29%

Peak VO2 above ISHLT
cut-off and normal STVR
(n=34)

Peak VO2 below ISHLT
cut-off and normal STVR
(n=9)
Peak VO2 above ISHLT
cut-off and abnormal
STVR (n=33)
Peak VO2 below ISHLT
cut-off and abnormal
STVR (n=28)

0

50

100

150

200

250

300

350

Duration of Event Freedom (Days)

Figure S3. Kaplan-Meier survival curves showing the cross-classification of the patient population into four
groups based on the peak VO2 below/above ISHLT cut-off and STVR below/above 1.3. Patients with normal
STVR showed the best event free survival regardless of their peak VO 2.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

References
1.
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of
vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration
Cooperative Study. N Engl J Med. 1986;314(24):1547-52.
2.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin
inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
3.
Shen L, Jhund PS, McMurray JJV. Declining Risk of Sudden Death in Heart Failure. N Engl J Med.
2017;377(18):1794-5.
4.
Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M, et al. Advanced
(stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J
Card Fail. 2015;21(6):519-34.
5.
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA
Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive
Summary A Report of the American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of
Heart Failure): Developed in Collaboration With the International Society for Heart and Lung
Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001;104(24):2996-3007.
6.
Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart
failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J
Heart Fail. 2018;20(11):1505-35.
7.
Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016
International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year
update. J Heart Lung Transplant. 2016;35(1):1-23.
8.
Lang CC, Agostoni P, Mancini DM. Prognostic significance and measurement of exercise-derived
hemodynamic variables in patients with heart failure. J Card Fail. 2007;13(8):672-9.
9.
Maurer MS, Schulze PC. Exercise intolerance in heart failure with preserved ejection fraction:
shifting focus from the heart to peripheral skeletal muscle. J Am Coll Cardiol. 2012;60(2):129-31.
10.
Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J, Kitzman DW. Effect of
endurance training on the determinants of peak exercise oxygen consumption in elderly patients with
stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol. 2012;60(2):120-8.
11.
Gmada N. A-HB, Haj Sassi R., Abdel Samia B., Bouhlel E. Relationship between oxygen pulse and
arteriovenous oxygen difference in healthy subjects: Effect of exercise intensity. Science & Sports.
2019:10.
12.
Chomsky DB, Lang CC, Rayos GH, Shyr Y, Yeoh TK, Pierson RN, 3rd, et al. Hemodynamic exercise
testing. A valuable tool in the selection of cardiac transplantation candidates. Circulation.
1996;94(12):3176-83.
13.
Metra M, Faggiano P, D'Aloia A, Nodari S, Gualeni A, Raccagni D, et al. Use of cardiopulmonary
exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients
with chronic heart failure. J Am Coll Cardiol. 1999;33(4):943-50.
14.
Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician's Guide to
cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association.
Circulation. 2010;122(2):191-225.
15.
Wilson JR, Rayos G, Yeoh TK, Gothard P. Dissociation between peak exercise oxygen
consumption and hemodynamic dysfunction in potential heart transplant candidates. J Am Coll Cardiol.
1995;26(2):429-35.
16.
Stringer WW, Hansen JE, Wasserman K. Cardiac output estimated noninvasively from oxygen
uptake during exercise. J Appl Physiol (1985). 1997;82(3):908-12.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

17.
Cohen-Solal A, Benessiano J, Himbert D, Paillole C, Gourgon R. Ventilatory threshold during
exercise in patients with mild to moderate chronic heart failure: determination, relation with lactate
threshold and reproducibility. Int J Cardiol. 1991;30(3):321-7.
18.
Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, et al.
Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of
abnormal peripheral oxygen extraction. Circ Heart Fail. 2015;8(2):286-94.
19.
Detry JM, Rousseau M, Vandenbroucke G, Kusumi F, Brasseur LA, Bruce RA. Increased
arteriovenous oxygen difference after physical training in coronary heart disease. Circulation.
1971;44(1):109-18.
20.
Higginbotham MB, Morris KG, Williams RS, McHale PA, Coleman RE, Cobb FR. Regulation of
stroke volume during submaximal and maximal upright exercise in normal man. Circ Res.
1986;58(2):281-91.
21.
Cattadori G, Salvioni E, Gondoni E, Agostoni P. Evaluation of noninvasive exercise cardiac output
determination in chronic heart failure patients: a proposal of a new diagnostic and prognostic method. J
Cardiovasc Med (Hagerstown). 2011;12(1):19-27.
22.
Sun XG, Hansen JE, Ting H, Chuang ML, Stringer WW, Adame D, et al. Comparison of exercise
cardiac output by the Fick principle using oxygen and carbon dioxide. Chest. 2000;118(3):631-40.
23.
Johnson BD, Beck KC, Proctor DN, Miller J, Dietz NM, Joyner MJ. Cardiac output during exercise
by the open circuit acetylene washin method: comparison with direct Fick. J Appl Physiol (1985).
2000;88(5):1650-8.
24.
Charloux A, Lonsdorfer-Wolf E, Richard R, Lampert E, Oswald-Mammosser M, Mettauer B, et al.
A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and
during exercise: comparison with the "direct" Fick method. Eur J Appl Physiol. 2000;82(4):313-20.
25.
Crawford MH, Petru MA, Rabinowitz C. Effect of isotonic exercise training on left ventricular
volume during upright exercise. Circulation. 1985;72(6):1237-43.
26.
Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria
based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163(7):670-5.
27.
Coffin M, Sukhatme S. Receiver operating characteristic studies and measurement errors.
Biometrics. 1997;53(3):823-37.
28.
Kato TS, Stevens GR, Jiang J, Schulze PC, Gukasyan N, Lippel M, et al. Risk stratification of
ambulatory patients with advanced heart failure undergoing evaluation for heart transplantation. J
Heart Lung Transplant. 2013;32(3):333-40.
29.
Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle heart
failure model - Prediction of survival in heart failure. Circulation. 2006;113(11):1424-33.
30.
Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and
prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac
transplant evaluation. Circulation. 1997;95(12):2660-7.
31.
Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical
outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant.
2004;23(12):1414-22.
32.
Goda A, Lund LH, Mancini DM. Comparison across races of peak oxygen consumption and heart
failure survival score for selection for cardiac transplantation. Am J Cardiol. 2010;105(10):1439-44.
33.
Diller GP, Giardini A, Dimopoulos K, Gargiulo G, Muller J, Derrick G, et al. Predictors of morbidity
and mortality in contemporary Fontan patients: results from a multicenter study including
cardiopulmonary exercise testing in 321 patients. Eur Heart J. 2010;31(24):3073-83.
34.
Williams SG, Cooke GA, Wright DJ, Parsons WJ, Riley RL, Marshall P, et al. Peak exercise cardiac
power output; a direct indicator of cardiac function strongly predictive of prognosis in chronic heart
failure. Eur Heart J. 2001;22(16):1496-503.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

35.
Laukkanen JA, Kurl S, Salonen JT, Lakka TA, Rauramaa R. Peak oxygen pulse during exercise as a
predictor for coronary heart disease and all cause death. Heart. 2006;92(9):1219-24.
36.
Oliveira RB, Myers J, Araujo CG, Arena R, Mandic S, Bensimhon D, et al. Does peak oxygen pulse
complement peak oxygen uptake in risk stratifying patients with heart failure? Am J Cardiol.
2009;104(4):554-8.
37.
Agostoni P, Corra U, Cattadori G, Veglia F, Battaia E, La Gioia R, et al. Prognostic value of
indeterminable anaerobic threshold in heart failure. Circ Heart Fail. 2013;6(5):977-87.
38.
Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: comparison
of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung
Transplant. 2011;30(11):1236-43.
39.
Gitt AK, Wasserman K, Kilkowski C, Kleemann T, Kilkowski A, Bangert M, et al. Exercise anaerobic
threshold and ventilatory efficiency identify heart failure patients for high risk of early death.
Circulation. 2002;106(24):3079-84.
40.
Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Technical considerations related to the
minute ventilation/carbon dioxide output slope in patients with heart failure. Chest. 2003;124(2):720-7.
41.
Ingle L, Goode K, Carroll S, Sloan R, Boyes C, Cleland JG, et al. Prognostic value of the VE/VCO2
slope calculated from different time intervals in patients with suspected heart failure. Int J Cardiol.
2007;118(3):350-5.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.21.19015610; this version posted December 27, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

